Read more

April 25, 2024
4 min watch
Save

VIDEO: Miebo improves dry eye signs, symptoms with ‘unprecedented’ safety

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating Miebo for the treatment of dry eye disease.

Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) demonstrated statistically significant improvements in both signs and symptoms in all patients analyzed. Sheppard also explained why the safety profile of Miebo is “unprecedented.”

“This data tells us that [perfluorohexyloctane] is a versatile, vehicle-only medication. It has a small drop size of 11 µL, it is well tolerated, it is water free and therefore preservative free, and patients have been responding magnificently since launch in my practice,” he said.